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Implantable technologies are becoming more widespread for biomedical
applications that include physical identification, health diagnosis, monitoring,
recording, and treatment of human physiological traits. However, energy
harvesting and power generation beneath the human tissue are still a major
challenge. In this regard, self-powered implantable devices that scavenge
energy from the human body are attractive for long-term monitoring of
human physiological traits. Thanks to advancements in material science and
nanotechnology, energy harvesting techniques that rely on piezoelectricity,
thermoelectricity, biofuel, and radio frequency power transfer are emerging.
However, all these techniques suffer from limitations that include low power
output, bulky size, or low efficiency. Photovoltaic (PV) energy conversion is
one of the most promising candidates for implantable applications due to
their higher-power conversion efficiencies and small footprint. Herein, the
latest implantable energy harvesting technologies are surveyed. A comparison
between the different state-of-the-art power harvesting methods is also
provided. Finally, recommendations are provided regarding the feasibility of
PV cells as an in vivo energy harvester, with an emphasis on skin penetration,
fabrication, encapsulation, durability, biocompatibility, and power
management.
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With advances in microelectronics
and nanofabrication, biomedical im-
plantable devices[1,2] now play an increas-
ingly significant role in the diagnoses,
treatment, and monitoring of various
diseases using miniaturized and high-
resolution biosensors,[3,4] reliable power
transducers,[5,6] and efficient integrated
circuitry.[2,4,7,8] A variety of subcuta-
neous devices such as defibrillators,[9]
pacemakers,[6,10] cochlear implants,[11,12]
drug pumps[13,14] as well as muscle, retinal,
and neurological stimulators[15,16] are now
being used for clinical applications. For
instance, to avoid sudden heart failure,
patients who suffer from heart diseases
require long-term heart rhythm monitor-
ing and analysis. Moreover, a defibrillating
shock is administered during cardiac ar-
rest. Such technologies work in harmony
with personalized medical devices (e.g.,
wearables) and have great potential for
real-world use.
However, power harvesting or generation is still a main chal-
lenge in such implantable devices. Most implantable devices
are powered solely using batteries, which need eventual surgical
replacement.[17] Some of the limitations of these devices include
their size, lifespan, and the risk of batteries leaking toxic haz-
ardous substances. Therefore, current miniaturization efforts re-
quire a reduction in the weight and size of these devices.[2] Due
to the limited battery capacity, there is an urgent need for trans-
ducers to harvest power from the human body or the ambient
environment to extend battery lifetime.
There are a variety of approaches for harvesting energy from
the subcutaneous environment using photovoltaic (PV) cells, ra-
dio frequency (RF) harvesters, piezoelectric generators (PEGs),
thermal electric generators (TEGs), biofuel cells (BC), as well
as other hybrid energy harvesting techniques. Figure 1c shows
the RF energy harvesting technique using a retinal stimulating
system.[18] Unfortunately, many of these techniques have limita-
tions due to their large size, low output power density, or unstable
energy output.
In comparison with the aforementioned approaches, im-
plantable PV cell technology converts abundant energy from the
sun into useful electrical power.[19] For PV power harvesters to
be effective in implantable devices, they need to deliver a steady
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Figure 1. Implantable biomedical power harvesting applications. a) A bio-implantable system of a neurostimulator,[1] b) A ultrasonic energy harvester
in usage of a cochlear hearing aid,[11] c) Retinal application powered by RF Energy harvester.[25] d) Thermal electric energy harvester in application of
Cardiac implants,[25,26] e) A enzyme biofuel generator collecting power from surrounding glucose, f) PV cell in application of neuro stimulator[27] and
g) The schematic diagram of the implantable applications, which contains four blocks: sensing block, power harvesting and conditioning block, signal
processing block, and signal communication block.[28] Reproduced with permission.[1,18] Copyright 2020, IEEE and Copyright Clearance Center.
and high output power density. The modular nature of PV cells
enables them to be configured and stacked with flexibility such
that the output power and voltage of an implantable application
can be met. Moreover, advanced methods have been proposed in
the literature to improve the efficiency of this technology using
light trapping techniques,[20,21] maximum power point tracking
(MPPT),[8,22] and other power management techniques.[22–24]
Nevertheless, there are challenges in using PV cells in im-
plantable applications, which include: 1) Rigid PV materials. Al-
most 90% of PV cell materials are on crystalline silicon materials,
which are rigid and require expensive manufacturing techniques.
To overcome these issues, emerging low-cost flexible materials
are becoming a competitive candidate. However, these fabricated
devices still suffer from low-grade performance and poor stabil-
ity. 2) Encapsulation needs to be transmissive to improve light
penetration in the PV cell, yet sufficiently protective to prevent
corrosion from the internal human body. The biocompatibility
and flexibility of the material used in encapsulation also requires
testing to avoid the side effects of the human body and to com-
fort the muscles. 3) Light reaching implantable PV cells is heav-
ily attenuated due to tissue losses, which limits the amount of
harvestable energy. Consequently, an investigation into how light
penetrates through different types of human tissue is required.
In fact, all implantable power harvesters need to be biocompati-
ble and sustainable for in vivo evaluation. In this case, all negative
side-effects to humans should be minimized.
Thus, in this article, we provide an overview of the energy
harvesting techniques that have been adopted in implantable de-
vices. We first present the typical power requirements of various
implantable devices. Next, we discuss the merits and drawbacks
of each technology. In particular, our article will focus on harvest-
ing energy from 1) light using PV cells, 2) motion using PEGs, 3)
electromagnetic energy using RF harvesters, 4) heat using TEGs,
and 5) biochemical energy using BC. We will demonstrate how
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Figure 2. The time development of implantable power harvesters and implantable applications associated with their power range. The dates as-
sociating with dash line are the first appearance in the implantable applications, and the power range is based on the works, including power
harvesters,[16,18,26,27,31–33,34] cardiac implant,[18,26,31,32] cochlear implant,[33] retinal implant,[16,31,34] drug pump,[31] and neural implant.[27,31] Repro-
duced with permission.[1,18] Copyright 2020, IEEE and Copyright Clearance Center.
these energy harvesters scavenge energy from the human body
as well as the external environment, as shown in Figure 1a,[1]
b,[11] c,[25] d[25,26] e,f.[27] Furthermore, we will discuss the latest
developments in implantable PV cells and highlight the latest
challenges in material synthesis, fabrication, encapsulation, and
light penetration.
2. Overview
Figure 1g demonstrates the typical components of an im-
plantable device. Variations in physical activity such as pressure
and temperature can be detected via an implantable dedicated
“sensing” block. The sensed signal can be processed by the
signal processing block via an analog to digital converter. Next,
the converted signal can be transmitted outside the human body
via the “communications” block. All these mentioned blocks
need to be supplied by power harvesting units that scavenge
energy from the human body or from the ambient.[28] Moreover,
all these blocks interface with biomedical sensors or actuators
subcutaneously.[29] The data sensing and conversion blocks are
able to detect the physiological data of the human body and trans-
fer it into an electric signal.[30] These signals can be processed
and stored as readable data by the signal processing module.
Subsequently, all these data are transmitted and received through
tissue using a signal communications block.
Our review will focus on the power harvesting technologies
that can be used to sufficiently drive the electronic components
in an implantable system. In this section, we will highlight the
amount of power required by each implantable application, as
well as the amount of power that can be scavenged using the dif-
ferent power harvesting techniques.
2.1. Implantable Applications
Figure 2 shows the power requirements of mature and emerg-
ing implantable systems, as well as the development of energy
harvesters for implantable applications.[16,18,26,27,31–34] Generally,
power requirements for implantable biomedical devices are in
the microwatt to milliwatt range. Voltage requirements are in the
range of 2–3V.[2] Figure 3 shows the development of using PV
cells for implantable applications.
In implantable device design, there are two approaches to opti-
mizing power consumption and delivery. The first involves min-
imizing the power consumption in functional blocks, whereas
the second involves increasing the power generation density.
Several design techniques were investigated to improve the
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Figure 3. The development of the implantable PV cells from 1999 to 2030. With 20 years development, the implantable PV cells are developed from a
proposed ideal to a mature technique with in vivo or in vitro test applied. 10 years development prospection (2020–2030) is also shown. a) The first
proposed idea of the implantable PV cell.[85] b) The first in vivo test of the implantable PV cell in animal.[86] c) The first on-chip CMOS PV cells.[80]
d) Using commercial PV cell to power a pacemaker.[87] I Diamond encapsulation of the implantable PV cell.[90] f) Flexible PV cell made by multilayer
flexible encapsulations.[89] g) The stacked CMOS PV cells with power management circuit.[81] h) First in vitro test of implantable PV cell in human
skins.[91] i) The first organic implantable PV cells (single-junction and tandem cells).[84] j) Small-area implantable PV cell in low-flux light condition.[103]
k) Prediction of hybrid PV with the other harvesters to help merge the energy. l) Integrated silicon PV arrays bonding with CMOS circuit.[27] Reproduced
with permission.[27,80,81,91,103] Copyright 2020, IEEE and Copyright Clearance Center.
performance of implantable devices, which include dy-
namic power-performance management and energy-efficient
signaling.[28]
The dynamic power-performance management includes en-
ergy harvesting, energy storage, and voltage conversion. Energy
harvesting and energy storage are used to extend the lifetime
of the implantable device. The voltage conversion for an im-
plantable device can optimize the voltage and current require-
ment of the loads.[28]
The energy-efficient signaling consists of low-power analog
and digital signal processing. Low-power analog signal process-
ing mainly reduces the power requirement of analog-to-digital
conversion by adapting dynamic range and the inconsistency of
the device. To mitigate the power loss from noise margin and
distortion of the digital circuit, the low-power digital signal pro-
cessing technique offers the reconfigurable and energy-efficient
digital architectures. The techniques provide the possibility to in-
crease the device lifespan and meanwhile decrease the power loss
in the loading and signal processing.[28]
As mentioned above, minimizing the power consumption
and losses can improve the lifespan of implantable biomedical
devices. In one case study, it was shown that decreasing the power
consumption of an implantable device from 10 mW to 8 µW in-
creases the lifespan of the implantable medical device from 3
days to 10 years.[28,35] Low-power components enable greater de-
vice functionality, whereas increasing the number of functional
blocks raises the power loads. In this case, the choice of power
harvesting technology depends on the application. Therefore, be-
fore selecting a particular power harvester, it is necessary to in-
vestigate the specifications and power requirements of different
implantable applications.
As mentioned above, cardiac pacemakers, cochlear hearing
aids, drug pumps, retinal stimulators, and neural stimulators are
mostly used in healthcare applications. The pacemaker was first
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invented in 1958, and over 200 000 patients survive from cardiac
dysrhythmias and heart failure using these devices.[9,10] The life-
time of pacemakers is normally 7–10 years, which requires years
of operation on battery charging instead of surgical replacement
(cost: $6000–$12 000).[2,9,28] The power consumption of the pace-
maker is normally in the microwatts range, and the device re-
quires minimal processing and low analogue-to-digital speed. For
special requirements, some pacemakers require high-energy car-
diac defibrillation, and the defibrillation has to be generated by
using large and intensive electrical pulse.[9]
In 1961, House from Los Angeles first installed cochlear
implants inside two patients with a hearing disorder. It was
designed to support or restore functional hearing by involving
electric stimulation. Compared to advanced implantable systems
like the pacemaker (250 000 patients in USA[36]), over 200 000
people received implantable hearing aids.[37] In fact, the hearing
aids market is largely attributed to the rapid development of
power management technologies.[38] Power consumption is
normally between 100 and 2000 µW. In comparison with the
pacemaker and cochlear applications, the retinal and neural
stimulators are emerging technologies. The power consumption
of stimulators varies from the micro to the milliwatts- range ac-
cording to the smart array configurations. The first neurological
implant in mammals was created in 1976 by Stenevi.[39]
Similarly, retinal implants were designed to restore a rudimen-
tary sense of vison for individuals with visual loss. They were first
designed and implanted by Brindley and Lewin in 1968.[40] Sim-
ilar to the neural stimulator, the power requirements of retinal
stimulators were associated with the electrode array configura-
tion. The drug pump system was designed in the 1960s and was
developed to replace oral administration in specific therapies.[41]
Compared to previous applications, the drug delivery system can
be inserted into different body locations that include intraocu-
lar, intrauterine, and vaginal sites. The system must be surgically
removed when the drug is exhausted which does not support ap-
plications as a long-term self-powered device.[14]
In the following sections, different energy harvesting methods
that have been used for various implantable applications will be
described. We discuss each technology’s working principles, as
well as its merits for meeting the power demands for implantable
electronic devices.
2.2. Implantable Energy Harvesters
2.2.1. Kinetic Energy Harvesting
Piezoelectric energy harvesting involves converting mechanical
energy to electrical energy. The direct piezoelectric effect is
well-suited for power harvesting that will induce a piezoelectric
potential attributing to the positive and negative charges of a
polar surface if an external force is applied on the piezoelec-
tric material.[2] The following coupled equation describes the
piezoelectric effect:
S = SE ⋅ T + dt ⋅ E (1)
D = d ⋅ T + 𝜀T ⋅ E (2)
where S is the strain tensor, T is the stress tensor, E is the electric
field, D is the electric displacement, SE is the compliance under
a zero or constant electric filed, 𝜖T is the dielectric permittivity
under a zero or constant stress, and d and dt are the direct and
reverse piezoelectric coefficients.[42]
The performance of piezoelectric systems is based on the char-
acteristics of the piezoelectric material. The first implantable
piezoelectric power system dates back to 1980.[43] To date, the
most common types of piezoelectric material are zirconate ti-
tanate (PZT), zinc oxide (ZnO), and polyvinylidene fluoride
(PVDF).[2] The first implantable PEG was fixed to a dog’s ribs in
1984.[44] Spontaneous breathing lead to a PVDF cell producing
18 V and 17 uW of output peak voltage and power. PVDF mate-
rial is advantageous since it is flexible and biodegradable, making
it suitable for wearable and implantable applications.[45]
PVDF material has been widely used in implantable devices.
In Yanhao’s work, the PVDF piezoelectric generator was embed-
ded with a polydimethylsiloxane package, and the whole package
was implanted into rodent muscle. The stability of output was
tested with an operating duration of 5 days. The average open
circuit voltage (Voc) and short circuit current (Ioc) were 3.8 V and
3.5 µA.[46]
In 2015, a novel flexible and implantable PVDF PEG with ca-
pacitor storage was proposed with a size of 56 mm× 25 mm× 200
µm. It was tested both in vitro and in vivo. For the in vitro case,
The maximum power output (Pmax), Voc, and Isc were 0.681 µW,
10.3 V, and 400 nA. As for the in vivo study, the maximum current
and voltage were 1.5 V and 300 nA when the PEG was attached
to the heart of a male domestic porcine. The output power be-
came 30 nW after 700 ms duration with 70 bpm heart rate. This
implantable PEG has shown the potential as power source for
low-power implantable electronic devices in the future.[32]
Another PVDF piezoelectric study showed the in vitro and in
vivo output power of 2.3 µW and 40 nW, respectively.[47] Other
PEG materials are described in Khan et al. (2016)[45] and Shi et al.
(2016).[48] Similarly, the output power for ZnO and PZT is in the
nW and µW scale.[45,48] ZnO material was used for encapsulation
with textiles to convert the wasted mechanical energy into electric
energy. Due to its quartzite crystal structure, PEG in ZnO can
work as a high-frequency resonator in microelectromechanical
systems (MEMS) or nanoelectromechanical systems. The PZT is
more commonly used compared with the other materials because
of the lighter weight. Although PZT suffers from a toxic nature,
it still validate in vitro and in vivo studies.[45]
A MEMS-based broadband piezoelectric ultrasonic energy har-
vester was previously developed to power implantable biomedical
devices. The system was able to generate output power of
1.47 µW (with tissue) and 0.047 µW (without tissue),
respectively.[48] Furthermore, this technique was FDA
approved.[18] To avoid cytotoxicity of the constituent materi-
als and immune response, PZT device could be encapsulated by
bio-compatible materials. The power density of PZT mechanical
energy harvester on the bovine heart in vitro demonstration
could reach 1.2 µW cm−2 and output peak voltage is as large as
8.1 V.[49] Furthermore, piezoelectric sensors could harness en-
vironmental vibrations and convert them into electrical energy.
For example, a 15 mm diameter PZT disc is involved to transfer
ultrasonic transcutaneous energy and power the internal unit
under a piece of pork muscle skin.[18,50] A power of 100 mW
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with 39.1% efficiency is successfully transferred at 650 kHz and
5 mm distance. The PZT material was utilized because of high
acoustic impedance. The acoustic matching layers were installed
on the active surface of PZT material and the backside was left
open to allow ultrasonic escape, which massively improves the
coupling energy into tissue. A Gaussian excitation of transmit-
ter approximation is applied to implement the ultrasonic to
overcome the limitation of uniform excitation.[18,50]
Therefore, piezoelectric energy harvesters can be designed
to be flexible and small to meet human body vibration require-
ments. However, PZT is still the most popular piezoelectric
material in recent devices, which is brittle and toxic. Thus, more
research is needed into advanced materials that are more flexible
and lead-free. Another limitation of piezoelectric transducers
is that they provide an AC voltage. Thus, an interface circuit is
required to convert AC to DC electricity. This process increases
system complexity and cost, and reduces the overall system
efficiency.
2.2.2. Bio-Chemical Energy Harvesting
BCs use living organisms to generate electricity and were first
demonstrated in implantable applications in 1974.[51] Biofuel
cells use biocatalysts to produce power. These cells can convert
bio-chemical energy to electricity via biochemical reactions. Liv-
ing organisms in the human body have biofuels (e.g., glucose
in blood) that are capable of generating power in microwatts
range.[52] The biofuel is oxidized at the anode of the biofuel cells
where the electrons are released, and the oxygen is reduced at the
cathode. The catalyst in the biofuel cells can be an enzyme that
can directly convert the carbohydrate chemical energy to electric
energy.[52]
Mesoporous carbons are used for the anodic biocatalyst for
glucose oxidation.[53] In 2009, Zhao et al. showed a comparison
between the electrical performance of the biofuel cells based on
the mesoporous carbons and carbon nanotubes.[53] The electric
performance of mesoporous carbon-based structure was much
more impressive than carbon nanotubes (CNTs) based structure,
which are (Voc = 0.82 V and Pmax = 38.7 µW cm−2) and (Voc
= 0.75 V and Pmax = 2.1 µW cm−2), respectively. Thus, it is a
strong proof that mesoporous carbons will be the novel type of
robust and advanced material for electrodes.[52,53] The biofuel cell
is modified by DNA wrapped single-walled carbon nanotubes. It
was found that the electric characteristics increased attributing to
the immobilization of glucose oxidase and active site protection.
Moreover, this novel structure will provide a tremendous power
density of 730–760 µW cm−2 with a duration of a week and the
stability of biofuel cells will be improved.[54] A dual power har-
vester combined with a TEG and biofuel cells was embedded with
0.18 µm complementary metal-oxide-semiconductor integrated
circuit. Simultaneous maximum power extraction of two power
generators is led to a control circuit to improve efficiency and
diminish the switching loss. Both harvesters obtain remarkable
electric power, which is 23 and 29 µW in TEG, respectively.[55] The
biofuel cell was fabricated with Lac-GAfCs-MWCNTs/GC cath-
ode and GOx-GAfCS-MWCNTs/GC anode, respectively, and the
cell operates inside the membrane-separated acetate solution at
pH 5. The output voltage, current density, and power density are
0.19 V, 114 µA cm−2 and 9.6 µW cm−2, respectively.[56]
Among the issues with biochemical energy harvesting is the
low power conversion efficiency, which means that a large area
is required. This makes them infeasible for implantable power
harvesting applications.
2.2.3. Thermal Energy Harvesting
Thermoelectric devices convert thermal energy into electricity via
the Seebeck effect. The Seebeck effect is a thermoelectric phe-
nomenon that involves converting a temperature difference into
a voltage difference. This phenomenon mainly occurs in metals
and semiconductors. Heating one end of a semiconductor causes
a temperature difference, which enables carriers to diffuse from
the hot to the cold ends of this semiconductor. Considering an
n-type semiconductor as an example, due to the high concentra-
tion of electrons, the majority carriers will diffuse from the heated
side to the cooler side in the semiconductor. The minority carriers
(holes) will in turn move in the opposite direction. In open circuit
conditions, negative charges at the hot end and positive charges
at the cold end are formed at either side of the semiconductor,
which results in an electric field to appear inside the semicon-
ductor. When the semiconductor reaches a stable state, the elec-
tromotive force caused by this temperature difference appears at
both ends of the semiconductor. Both p and n type semiconduct-
ing materials are required to cause current flow in a thermoelec-
tric generator.
Thermal energy harvesting has been used in many sensing
applications.[57] The thermoelectric effect can be described by the
following equations:[26]







where VG is the output voltage, 𝛼 is the Seebeck coefficient of
thermal material, N is the number of the thermocouples, RL is
the loading resistance, Rin is the internal resistant of TEG and
PL is the output power. It is well known that the human body is
an unlimited heat source, which leads to great potential in im-
plantable energy harvesting.
The first implantable thermoelectric power harvester was
demonstrated in 1970.[58] The most common semiconductor
material for thermoelectric power harvesting is polycrystalline
silicon germanium (poly-SiGe) and bismuth telluride (Bi-Te).
However, due to its high ZT properties and room temperature
fabrication capabilities, Bi-Te is mainly used for commercial
applications.[59] In comparison to poly-SiGe, Bi-Te can gener-
ate between 19 and 30 µW mm−2 with 27–70 K temperature
difference.[60]
Thus, thermoelectric generators have many advantages that
include its lightweight and flexibility. However, these energy
harvesters are not ideal in environments that have a similar
temperature to the human body.[61]
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2.2.4. Radio Frequency Energy Harvesting
Radio Frequency energy harvesting involves scavenging power
from electromagnetic radiation. The first RF energy harvesters
were demonstrated in pacemakers back in 1969.[62] RF waves can
be classified as near-field or far-field, depending on the electro-
magnetic waves in the different distance (specified by Fraunhofer
distance).[63]




















where M is the mutual inductance between the transmitting and
receiving coils, Lf is the inductance of transmitting coil at fre-
quency f, V1 is the supply voltage at transmitting end, V2 is the
charging voltage at the receiving end, R2 is the resistance at the







where PT is the power in transmitting antenna, GT and GR are
the transmitter and receiver antenna gain, respectively. 𝜆 is the
wavelength of the electromagnetic wave.
A neural interface microsystem was powered by an inductive
link at 2 MHz which was supplied by a Li-ion battery.[18,65]
The power link consisted of a 210-pF ceramic capacitor and a
27-turn 27 mm AWG 40 strand Litz wire with the inductance of
2 𝜇H. Such coil was advantageous of a high-quality factor (Q)
of 75.4 with 2 MHz.[18] A Copper based on the ceramic coil was
embedded in a 9 mm2 chip which is implanted in human retinal
to produce artificial vision. Five subjects such as light perception,
localization and motion detection were tested by patients. The
copper in the polyimide coil was applied at the far-field frequency
of 910 MHz was operated. In this case, the possibility of RF en-
ergy harvesting inside moving small animals was approved and
the completely wireless behavior can be controlled.[18,66] Energy
was coupled from a copper power link in Ferro solution to reso-
nant energy into a head borne device a maximum magnetic field
of 300 A m−1. These in vivo experimental results were tested in a
rat inside a cage-like power transducer at a resonant frequency of
120 kHz. The device was orthogonal to the cage to optimize the
magnetic coupling.[18,67] In 2010, two on-chip antennas were em-
bedded with circuit by using 0.18 µm technology. A remarkable
power scavenging distance of 7.5 cm was achieved, and mean-
while 13.2 µW cm−2 power was harvested by the downlink. There
was no-off chip components used in this research.[68] In 2011, a
loop antenna was applied in an intraocular monitor, and the bio-
compatible methacrylate plastic and small size make it as a good
candidate in retinal application. The power density of 28.33 µW
cm−2 was achieved in 1.5 cm at −10.5 dBm RF sensitivity.[69] In
2018, the circular polarization was considered in antenna design,
and the antenna had a relatively smaller size and can obtain a
better electromagnetic radiation. After tested under a 4 mm skin,
9.65 µW cm−2 power density was obtained in a distance of 40 cm
at 915 MHz.[70]
It must be emphasized that the power density of near-field
RF is unpredictable compared with far-field RF, which is nor-
mally considered as uniform.[63] The different magnetic flux
density in near-field and far-field range make the RF harvester
facing different challenges associated with these ranges. The
near-field RF requires perfect impedance matching and antenna
alignment, which is still a challenge for designers. According to
the low far-field magnetic flux density, it is difficult to harvest
sufficient energy to start up the circuit by using far-field RF
harvester, where the start-up thresholds are different in different
CMOS technologies.[71] In addition, the frequency of far-field RF
harvester is limited up to GHz range as a result of tissue loss.[71]
2.2.5. Photovoltaic Energy Harvesting
Harvesting energy from light has been used for powering
portable consumer products. Here, PV cells are used to convert
light or the sun’s energy into useful electricity. Ultimately,
semiconductor materials are commonly used for the purpose of
producing currents and voltages as a result of the absorption of
light, which is a phenomenon known as the photovoltaic effect.
Most PV cells are fabricated from either monocrystalline or
polycrystalline silicon (Si) materials. In its most basic form, a PV
cell consists of a pn-junction diode. Typical PV cell efficiencies
range from 18% for polycrystalline to 24% from highly efficient
monocrystalline technologies.[72] These high-end PV devices
typically include special light trapping structures that absorb as
many of the incident photons as possible.[20]
The I–V characteristics and the output power of a typical PV
cell can be described by:[73]
I (V) = Isc − Id −
V + I (V) Rs
Rsh
(8)
Pout = Isc ⋅ Voc ⋅ FF (9)
Where Isc is the short-circuit current, Id is the dark current,
Rs is the series resistance of PV cell, Rsh is the shunt resistance
of PV cell, Voc is the open-circuit voltage and FF is the fill factor.
For implantable power harvesting applications, PV cells
cannot harvest in vivo bioenergy directly, but it can harvest
energy from an ambient light source (natural light or artificial
light).[74]
In this section, we will initially demonstrate the development
of implantable PV cells. We will also compare PV cell perfor-
mance using different materials and technologies. Next, the fab-
rication process of PV cells and the encapsulation techniques
will be discussed. Here, it is important to emphasize that en-
capsulation involves protecting the PV cells as well as reducing
the adverse side effects to humans. We will mainly discuss the
transmissivity, flexibility and biocompatibility of the encapsula-
tion material. Optical losses due to tissue scattering effects will
be analyzed and the optical properties of different skins will also
be summarized.
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Figure 4. a) The normalized power from the different implantable power harvesters according to the active area of the devices, where the piezoelectric
generator (PEG), biofuel cell (BC), thermoelectric generator (TEG), radio frequency harvester (RF) and photovoltaic (PV) cell are included. All the
harvesters were tested in in vivo and in vitro, and the PV cells were under in vivo and in vitro testing under different light density. b) The harvested power
changes of the implantable PV cells from 2012 to now.
2.3. Comparison between Implantable Power Harvesters
Figure 2a–j demonstrates the power consumption of various im-
plantable devices and the harvestable amount of power by dif-
ferent technologies. The voltage requirements for a commercial
implantable device is 2–3 V.[2] Batteries can satisfy the power
and voltage requirements for implantable devices. However, their
large size and weight restrict their use. In addition, there are
chemical leakage risks that can cause damage to the body.[75]
Thus, for an implantable power harvester to be effective, it must
have a smaller size, better lifetime and provide sustainable power.
Figure 4a shows a comparison between the power density that
can be generated from different power harvesting approaches.
Clearly, implantable PV cells can harvest the highest power den-
sity. RF energy harvesters can generate high power in the near-
field, but careful alignment is necessary. Far-field RF harvesters
are inefficient when the frequency is increased to tens of GHz.
The start functioning and magnetic field mismatch are the main
constraints.[63,71,76] To be specific, the RF system requires power
to wake up the system because the CMOS components always
have a threshold, but far-field RF harvesters are inefficient. A
perfect match between transmitting and receiving coils can in-
crease the magnetic flux density, hence improve the power out-
put. Large coil size, short power range and tissue losses are
lingering challenges.[18,77]
As discussed before, PEG can harvest kinetic energy from hu-
man motion.[45] As can be seen from Figure 4a, the size of PEGs
is larger than PV cells, BCs, and TEGs. Some PEGs have a small
size, but the harvested amount of power is low. Another prob-
lem of PEGs and triboelectric nano generators (TENGs) is the
unstable and low output voltage. Both these technologies need
to be implanted into moving organs such as the heart, lungs,
or in the pericardial region. However, the size, rate and exter-
nal force of the organ affects the output voltage of the PEGs.[2]
Notice that similar to PEG, TENG is a new type of kinetic en-
ergy harvester based on the conjunction of triboelectrification
and electrostatic induction.[6] Such an energy harvester can be
driven via rat breathing, thus enabling in vivo power delivery to
the pacemaker.[6] Besides, the TENG has also been used to scav-
enge energy from the heartbeats of a porcine and was able to sup-
ply power to a real-time cardiac monitoring system.[78] Yet, both
refs. [6] and [78] only provide limited data and cannot be directly
compared using Figure 4a.
BCs are highly biocompatible with living organs, since they
are often tested with plants, insects, and even mammals.[55,79] Ac-
cording to Figure 4a, the amount of harvestable power from BCs
is similar to PEGs, but their size is relatively small. Although BCs
are advantageous due to cheap fabrication costs and high biocom-
patibility, the degradation of the enzyme is still a challenge. Com-
pared with other power techniques, TEGs highly depend on the
temperature changes, but the maximum temperature difference
in human body is less than 6 °C.[26]
Implantable PV cells have commonly been used as small-
scale harvesters and have been demonstrated to generate power
from ambient light. In addition, the introduction of light man-
agement techniques, power management circuits, MPPT con-
trol logic and start-up circuits will tremendously improve the
performance of implantable solar cells.[24,80,81] Most importantly,
new developments in solar cell technologies have enabled multi-
crystalline PV cells to achieve an efficiency improvement from
21.9% to 22.3% within one year (2017–2018). Furthermore, new
and emerging materials such as perovskite have enabled a 1.2%
increase in solar cell efficiency.[82]
3. Implantable Photovoltaic Cell
3.1. Development of Implantable PV Cells
Concerning the development of implantable PV cells, several im-
provements have been made with respect to materials, device
configuration, encapsulation and stability. The major milestones
of these developments are shown in Figure 3. The development
in power density of implantable PV cells in terms of harvestable
power changes since 2012 is depicted in Figure 4b. Before 2012,
implantable PV cells occupied a larger area due to the CMOS
technology available at the time. Between 2010 and 2014, im-
plantable PV cell technology developed according to advance-
ments in CMOS technology.[80] The on-chip PV cell was invented
during this period.[80,83] Between 2014 and 2018, the literature
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Table 1. A comparison of different types of Implantable PV cells.




Package Flexibility Biocompatible Application Reference
Crystal Mono-Si Outdoors 1000 4.94
b)
Silicone No Yes Cardiac [87]
Mono-Si NIR 2000 2.21
b)
PLGA Yes Yes LED [104]
Mono-Si NIR 1000 2.13
a)
– No No Temp. [100]
Mono-Si simulator 1360 6.17
a)
– No No Sensor [80]
Mono-Si Halogen 12.2 18.87
b)
– No No – [81]
Mono-Si NIR 7000 9.35
b)
Diamond No Yes Cochlear [90]
GaInP/GaAs AM1.5G simulator 1000 8.46
b)
PDMS Yes Yes Cardiac [89]
GaAs NIR 1500 44.12
b)
Silicone/resin Yes Yes Retinal [86]
GaAs µ-ILED 430 42.29
b)
– No No Neural [102]
Non-crystal a-Si Halogen 100 0.95
b)
Silicone No Yes Cardiac [85]
a-Si Outdoors 1000 0.06
b)
Silicone Yes No Temp. [105]
Organic NIR 1000 3.84
b)
– Yes Yes Retinal [84]
a)On-chip PV cells; b)Off-chip PV cells.
showed a shift toward lower power density PV cells. Perhaps this
could be attributed to an increased commitment toward better
biocompatibility and encapsulation issues. After 2018, emerging
technologies such as organic PV cells were demonstrated in im-
plantable applications[84] without encapsulation.
Among the first researchers to propose the use of PV cells for
implantable applications was Dan Tchin-iou in 1999.[85] A source
providing light in the visible range was used to power a commer-
cial solar cell with an integrated battery pack. This system was
used to power an artificial heart. However, this research lacked
analysis of tissue loss and under-skin device validation (in vitro
or in vivo). In addition, the light source was confined to wave-
lengths in the visible range and did not consider light in the red
and infrared ranges.
The first in vivo testing of an implantable PV cell was achieved
by Thomas Laube in 2004.[86] A near infrared (NIR) light source
was used and PV arrays were encapsulated with a resin. The
PV cells were embedded in an intraocular microsystem, and the
whole chip was implanted into a rabbit. The system was tested in
vivo for 7 months, which is the longest testing duration for any
implantable device to date. In addition, full information about the
surgical procedure and recovery treatment were provided.
Between 2004 and 2012 there were no published articles in
the area of implantable PV cells. During this period, implantable
PV cells were discarded energy harvesters due to their size and
due to the risk of infection from the connecting wires. However,
thanks to advancements in integrated CMOS technology, there
has been a renewed interest in using PV cells in 2012. In fact, Sa-
har Ayazian proposed a self-powered and fully integrated system,
which embedded power-harvesting PV cells and sensor arrays in
a 2.5 mm × 2.5 mm CMOS chip. They demonstrated successful
power harvesting in the microwatt range for a device that was im-
planted 3 mm below chicken skin. They tested the feasibility of
using a CMOS PN junction as a potential PV power harvester.[80]
Furthermore, Haeberlin et al. successfully demonstrated a PV
driven pacemaker using thin film silicon materials ,[87] which was
tested in vivo tested for 40 days in 2015.[88] The power density of
their device was 0.95 mW cm−2, as shown in Table 1. To scavenge
more power, expensive semiconductor materials such as GaAs
and GaInP, are needed.[89] The power density of GaInP/GaAs was
8.46 mW cm−2 under AM1.5G condition.[89] The GaAs PV cell
achieved higher power density of 44 mW cm−2 by using NIR light
source.[86] However, a better encapsulation would be required
due to the toxicity of these materials. For example, Ahnood et al.
demonstrated a diamond capsule for implantable PV cells, which
was used both as a package and an optical window due to its high
mechanical robustness, biocompatibility, and wide transmission
spectrum.[90]
Considering the comfortability of the patient, flexible PV cells
are used in the Implantable system by Song et al. in 2016. The
PV cell was encapsulated with polymethyl siloxane (PDMS). The
device can successfully supply a commercial pacemaker in a rat
with the power of 8 mW cm−2. To test the biocompatibility of the
device, the amount of Arsenic was measured by using a mass
spectrometer, and the 0.02 µg leakage by using emerging PDMS
is lower than the daily intake from air breath (0.6 µg) and water
(20 µg) by a person.[89] As the power output of the PV cell highly
depends on the feature of covered skins, it is necessary to test
the performance of the cells under human skins even if there
are a lot of studies showing the viability in the animals. In this
case, the performance of the PV cell under fresh and fixed human
skins were measured in different location in 2017. The results
(2.34 mW cm−2 under inner arm, 2.21 mW cm−2 under hand
dorsum, 0.96 mW cm−2 under forehead) shows that the device
under inner arm can provide most power output within same
incident optical power.[91]
Organic PV (OPV) cells were also used for retinal applications
due to their sensitivity to NIR light.[84] The authors demonstrated
both single-junction and tandem OPV cells based on a bulky het-
erojunction. They investigated the voltage and storage charging
time of the stimulating electrode in a saltine solution via electrical
pulses. Since the Voc of tandem PV cells (1.31 V) was higher than
that of single-junction PV cells (0.67 V), the tandem PV cell was
able to provide a full charge per pulse stimulation window in NIR
light conditions. In addition, the efficiency of the tandem PV cell
was higher (5.6% in comparison to 5.3% in the single junction).
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For safety concerns, the light intensity in retinal applications was
limited from 150 to 600 mW cm−2. In this scenario, the tandem
OPV with an active area from 2500 to 6250 µm2 and electrode di-
ameter of 35 µm can efficiently tune the charge per pulse, while
the electrode of single-junction OPV was 60 µm, which limits the
implantable resolution.
In summary, commercial PV cells were tested in vivo and
used for implantable applications between 2000–2010. In effort
to reduce the size of these cells (and increase the power den-
sity), CMOS technology was used after 2010 for fabricating both
the on-chip PV cells and the power management circuitry. In
the period between 2014 and 2017, researchers began using im-
plantable PV cells to power real devices such as pacemakers.
Moreover, encapsulation materials were used to protect device
and ensure it is biocompatible. During this period, in vivo testing
in animals and in vitro testing in human skin types were under-
taken. Since 2018, emerging PV technologies such as organic PV
cells were used in implantable applications.
3.2. Material and Technologies
Implantable PV cells harness light in the NIR range more effec-
tively due to scattering losses from tissue.[75] However, there are
issues with heating as a result of NIR light, which might cause
discomfort to the wearer.
PV cells can be divided into two broad categories: crystalline
and non-crystalline materials. Crystalline solar cells are typ-
ically more efficient, more expensive and less flexible than
non-crystalline materials.[92] In 2015, around 93% of all PV
cells were made from crystalline silicon materials, with 24%
of this share from monocrystalline Silicon and 69% from mul-
ticrystalline Silicon.[93] Today, almost 89% of solar cells are
fabricated from crystalline silicon, 10% from amorphous silicon
and 0.5% of Cadmium telluride, dieseline, copper indium and
gallium arsenide.[94] Table 1 compares the output power density,
flexibility, biocompatibility between the different material or
technologies.
Due to their mature technology, Si, GaAs, and GaInP are typ-
ically used in implantable applications.[81,89,95] Compared with
silicon, gallium is a soft metallic material that is often com-
bined with a compound such as As, N and P. Such materials
are often called III-V compound semiconductors.[96] Gallium ar-
senide (GaAs) is particularly suited for NIR light absorption due
its higher bandgap and lower reverse saturation current. Conse-
quently, these materials normally have a better EQE in the NIR
region, while amorphous silicon (a-Si) is better suited to visi-
ble light.[97] Moreover, due to the issues with heating, GaAs is
less sensitive to heating (0.14 to 0.15 Ohm resistance variation
based on the temperature coefficient from 0 to 50 °C[98]) and has a
higher breakdown voltage. For instance, the breakdown voltages
of GaP and GaAs at 1015 cm−3 doping gradient are approximately
800 and 300 V in comparison to 200 V for Si.[99] However, the
toxicity and higher cost are the main limitations.
Apart from wafer-based PV cells, biodegradation of thin-film
silicon PV cells have been investigated in different conditions.[97]
In comparison to the cutting and sawing process of wafer-based
cells, the fabrication of the thin-film cell needs microelectronics
processing techniques.[97] The most common materials used for
thin-film PV cells are a-Si, microcrystalline silicon (𝜇c-Si), and
mono crystalline silicon (c-Si). During the fabrication process,
c-Si thin film cells are formed using the transfer printing pro-
cess, while a-Si and polysilicon thin films are formed using the
chemical vapor deposition (CVD) process. In contrast, OPV cells
are advantageous due to their high flexibility, low cost and ease
of fabrication.[92] They can be a good candidate for implantable
applications if the energy conversion efficiency can be improved,
and the stability of the cell can be prolonged.
Currently, there are two types of PV cell architectures that are
used in implantable applications: CMOS[27,75,80,81,86,89,91,95,100–104]
and commercial PV cells.[85,87,90,105] Table 1 compares the output
power density, flexibility, biocompatibility between the different
materials and technologies. On chip PV cells are fabricated using
standard CMOS technology, which applies the diode formed by
N+ region, P+ region, N well, p well, deep N well and p substrate.
Figure 5a,b demonstrates a PV cell design with circuitry based on
CMOS technology.[106] One P+/N-well PV cell and one N+/P-sub
PV cell were used as the PMOS source and NMOS source. Each
PV cell was able to supply 0.3–0.4 V and different configurations
of PV cells can provide different voltage output.[81,106]
During the fabrication process, the CMOS circuit is often
shaded by a metal layer to avoid leakage of photo-generated cur-
rent in the circuit. In fact, the on-chip PV cell occupies a smaller
area than an off-chip cell, since all the components are integrated
into a single block. However, the efficiency of on-chip PV cells
is typically lower (<20%) and the negative voltage formed by re-
versed junctions and the P substrate connected to ground makes
it difficult to make different PV cell configuration.[81]
Figure 5b shows a PV cell fabricated in the laboratory instead
of using CMOS technology.[89] Compared with the conventional
use of monocrystalline silicon and the limited stacking topologies
of CMOS technology, off-chip PV cells can be based on a variety
of materials (inorganic and organic) and stacking topologies. For
instance, heterojunction PV cells were previously fabricated us-
ing GaInP/GaAs materials in a 2 x 7 array to drive a load.[89]
CMOS technology can also be used to fabricate off-chip PV
cells by thinning the p-type substrate to 60 µm[75] and back illumi-
nating the cell. In that case, instead of grounding the substrate, it
is left floating. Furthermore, it would not be possible to integrate
this off-chip PV cell with other power management circuitry due
to this to floating substrate. Figure 5c,d shows two types of off-
chip (back-illuminated) PV cells[75] with an improved efficiency
of 18.3%.[75]
3.3. Encapsulation
Encapsulation is necessary to prevent the electronic circuitry
from corrosion. Conventional encapsulation is based on ceram-
ics, glass and metals, such as the Titanium and ceramic pack-
aging. In the pacemaker and other similarly packaged implants,
most of the titanium shell is exposed to body fluids. This is ac-
ceptable if all exposed metal surfaces (including tracks) are at
the same potential. Such implants sometimes use metal in glass
feedthrough, although this is becoming common.[94]
Metals, glass and ceramics are highly biocompatible materials.
They are stiff and have a low permeability to water vapor.[107] Al-
though these conventional materials are advantageous in harsh
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Figure 5. The structure of the implantable PV cells: a) the equivalent circuit and cross-section of the integrated PV cells with circuitry fabricated by CMOS
technology,[106] and b) a home-made PV cells 2 × 7 arrays in GaInP/GaAs according to the work implemented.[89] c,d) The unit cell layout views of the
finger type and leaf type junction designs: Finger-type junction design in CMOS on-chip PV cell (c) and Leaf-type junction design in CMOS on-chip PV
cell (d).[75]
physical environments, they are not compatible with the CMOS
fabrication process.[107,108] Consequently, novel encapsulation
materials have been investigated such as SiO2, SiC, Al2O3, dia-
mond, as well as organic silicone polymers, polyimide, PDMS,
liquid crystals and SU-8.[108] The parameters of these emerging
materials are shown in Figure 6a–d.
There are two types of implantable encapsulation methods:
1) encapsulation for a conformal layer, 2) encapsulation for an
impermeable envelope. As shown in Figure 7a,b, the encapsu-
lation and packaging techniques are predominantly composed
of Hermetic packages and polymer encapsulation. The polymer
encapsulation is one of the highly reliable techniques to protect
the electronic components from the subcutaneous environment,
which is shown in Figure 7b.
Soft encapsulation typically provides greater comfort to
patients.[109] Silicone rubber is attractive in this encapsulation
technique because it can greatly prevent the ambient fluid from
shorting conductors and long-duration corrosion damage from
water vapor.[109] However, the cleanliness and absence of voids
are still challenging to obstruct the performance the implantable
electronics. To avoid these problems, the adhesive connection
between the layers in the encapsulation must maintain strong
for the whole required lifetime of the implantable device. If the
adhesive layer is not strong enough, the pressure caused by ionic
liquid outside will damage the adhesive bond and drive the water
vapor into the voids in the encapsulation, which causes the in-
crease of humidity inside of the encapsulation. Besides, the poly-
mer encapsulation is tremendously reliable when the large-size
discrete components in simple circuitry are applied.[109] Nowa-
days, the integrated circuit (IC) is routinely applied as a part
of an implant. It is quite necessary to investigate the ability of
polymer encapsulation alone to protect the bare IC chips, other-
wise, this technology will only be adaptable for the short-term and
medium-term implantable applications.[109] The Hermetic pack-
age is based on a solid water-impermeable shell and hermetically
sealed, which is shown in Figure 7b. The hermetic package can
protect the electronics from the ambient fluids and maintain the
humidity at a low level. However, it requires the material to be
impermeable to vapor.
When considering the encapsulation of photovoltaic-driven
implantable devices, there are three factors which can sig-
nificantly influence the selection of novel materials: optical
properties, biocompatibility, flexibility and lifetime. Figure 6a–d
shows the variation in the physical properties of the encapsu-
lation materials. Figure 6a shows the variation in the refractive
index of the encapsulation materials as a function of wavelength
for the following materials: Crystalline alumina (𝛼-Al2O3),
[110]




[113] thin-film SiO2 ,
[114]
diamond,[115] polyimide,[116] parylene,[117] silicone (PDMS),[110]
liquid crystal polymer (LCP).[118] Similarly, Figure 6b shows the
variation in the extinction coefficient as a function of wavelength
for the same range of materials. It is noteworthy to mention
that the refractive index of these materials is close to 1.5 in the
visible and NIR region, which is very close to the refractive index
of human skin.[119] In addition, the extinction coefficient of the
materials is close to 0 in the visible and NIR range, meaning that
the absorption of the light is small and achieving high optical
transmittance.
In Figure 6c, the lifetime and mean time to failure (MTTF)





parylene,[108,124] silicone,[108,125] and LCP.[108,124] The MTTF of
these materials is obtained by placing them in a specific
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Figure 6. Variation in the encapsulation material properties: a) refractive index as a function of wavelength, b) extinction coefficient as a function of
wavelength, c) lifetime in body temperature and mean time to failure, as well as d) Young’s modulus.
Figure 7. Two types of implantable encapsulation or packaging: a) polymer encapsulation, which is applied in the implantable devices, and b) the
hermetic package which is applied in the implantable devices.
temperature, and the long-term reliability is validated by plac-
ing the samples in a saline solution in accelerated aging experi-
ments. The lifespan of these materials in the human body can be
obtained from the MTTF values (reaction rate in saline solution)
and other properties of the materials. It is clear that inorganic ma-
terials such as Al2O3, HfO2 and SiO2 have longer lifetimes than
organic materials, since they are more sensitive to sterilization
than their inorganic counterparts.[108]
The flexible encapsulation of the chip can massively increase
in fracture strength of up to 190% and curvature of bending
85%.[126] To understand the flexibility of the encapsulation, it
is significant to examine their mechanical properties. Figure 6d
shows the variation in the Young’s Modulus for different
materials. Generally, a high Young’s modulus means the ma-
terial is difficult to bend and has poor flexibility according to
same geometry.[126] The geometry also influences the flexibil-
ity. For example, a ultra-thin chip with thickness <20 µm have
been investigated to obtain a compact high-performance flexi-
ble electronics.[126] Table 2 shows the fabrication processing and
physical properties of the encapsulation materials.[108] The phys-
ical properties such as thermal expansion coefficient, resistivity
and moisture absorption are factors that affect the biocompati-
bility of the encapsulation. We will discuss the different types of
encapsulants in the following paragraphs.
For example, alumina (Al2O3) is considered as a good encapsu-
lation material with high biocompatibility, and it typically works
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Al2O3 ALD+CVD 6.052 4 × 104 °C−1 4.75 at 30 °C No 1 –
HfO2 ALD 0.1 – – No 1 –
SiO2 Thermal 0.1–1 4.5 × 104 °C−1 6.04 at 30 °C No – –
Diamond CVD 300 – – No – –
Polyimide Spin coating 10 40 ppm °C−1 3 Yes 1000 1016
Parylene C CVD 6–40 35 ppm °C−1 – Yes 1 8.8 × 1016
Silicone CVD 40 340 ppm °C−1 – Yes – 2.9 × 1016
PDMS Spin coating 150 – – Yes – –
as the feedthrough with a titanium package.[108] It provides a
good moisture barrier and demonstrates high RF transparency.
Alumina offers conformal coverage over a surface and provides
pinhole-free films.[108] However, this material requires a labor-
intensive process for assembly and has similar miniaturization
issues with metals and glass.[108] Moreover, Alumina exhibits an
extinction coefficient of null at 635 nm and a refractive index of
1.77 at 635 nm.[127] Moreover, the inorganic encapsulation pro-
cess is based on CVD. For instance, the Al2O3 is normally de-
posited by ALD and CVD, SiO2 combines Thermal bonding and
CVD. However, the organic encapsulation formation including
polyimide, silicone, PDMS, LCP is normally achieved by using
spin coating, thermal bonding.[108] Despite the Parylene C, it nor-
mally applies CVD for complex surface topography with crevices
and sharp edges.[108]
Other materials include HfO2, which is often applied as the
conformal coating over nanoscale devices using the atomic layer
deposition (ALD) technique. It has great thermal, mechanical,
and chemical stability.[108,128] It also exhibits a null extinction
coefficient from 300 to 10 000 nm with a refractive index of 2
(5000 nm)–2.18 (365 nm).[127] Recently, HfO2 was involved in
hermetic packaging to be the extra moisture barrier between the
organic layers or working as a multi-stack in the encapsulation
layer.[129]
Silica (SiO2) is typically applied in laser welding and anodic
bonding. However, minimization is an issue for this encapsula-
tion material.[108] Deposition of the SiO2 layer uses the same CVD
and ALD techniques as PV cells.[122] The refractive index of silica
is 1.52–1.65 (198–2000 nm) and the absorption coefficient is 2.63.
In that case, the transmittance is 99% for a 1 µm thick material
and drops to 77% when the thickness is increased to 1mm.[130]
Diamond is an emerging biomedical encapsulation ma-
terial due to its mechanical stiffness, wear and chemical
resistance.[108,131] The encapsulation process requires high tem-
perature and pressure. Its optical properties makes them ideal for
implantable PV cells.[90] Ahnood et al. demonstrated CVD grown
diamond plates to form the substrate. The optically transparent
single crystal diamond was applied as the optical window layer of
the encapsulation. The electrode interconnection to the PV cell
was installed in the window top layer.[90]
Moreover, Polyimide has a thermal expansion coefficient of 40
and has 2–3% vapor absorption. Polyimide is normally applied
in neural implants.[108] The polyimide can be compatible with
the majority of MEMs processes (photosensitive polyimide in
photolithography and polyamide adhesion in bonding). Parylene
is advantageous in a thin conformal layer, it is flexible, inert and
has excellent optical transparency (the refractive index and ex-
tinction coefficient are shown in Figure 6a,b). Until now, polymer
encapsulation was mostly used for implantable PV cells due to
its flexibility. The materials of these encapsulations are silicone,
PDMS, PLGA and the other polymers. For example, GaInP/GaAs
PV cells were capsulated with multilayers of biocompatible and
transparent polymers, including 2 µm of SU-8 and 100–200 µm
of PDMS.[89] The simple and flexible structure of these polymers
make them mechanically compatible with human tissue, and
the adhesive layer can prolong the lifetime of the package.[89]
Silicone is commonly used as a encapsulant for optical
devices such as LEDs, photodetectors and PV cells due to its
transparency and wide refractive index range (1.38–1.58).[132]
Moreover, silicone meets the typical requirements of the health-
care and electronics industries due to its low dielectric constant
(2.68 at 100k Hz), high thermal conductivity (0.4–1.34) and low
resistivity (2.9 × 1014 Ω m).[132] For encapsulation purposes,
silicone rubber provides good protection in the comfort layer,
and it can be integrated with a ceramic material to develop
an impermeable envelope. The advantages of silicone are as
follows: 1) The outer layer is biocompatible, and the sharp layer
is covered to protect the host body. 2) Corrosion of the exposed
metal electrode is prevented from corrosion. 3) Silicone insulates
the feedthroughs that carry the signal in and out of the sealed
enclosure. In addition, Silicone can be applied as the sealant of
frame and junction box for PV cells.
3.4. Skin Properties and Losses
Skin aims to protect the internal organs from light. Consequently,
harvesting energy from ambient light using implanted PV cells
becomes a challenge. Thus, light will be attenuated due to tis-
sue losses. Furthermore, different skin types will attenuate light
differently.[133] In this section, the properties of different skin
types will be explained, and the influence this has on the per-
formance of implantable PV cells will be demonstrated.
Skin is a complicated medium, and its optical parameters dy-
namically vary with temperature, hydration and radiation. Fur-
thermore, light propagation through skin depends on absorption,
scattering, transmission and reflection between tissue bound-
aries. These boundaries are the interfaces between two media
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Figure 8. a) The structure of human skins. As a multi-layer structure, the skins are composed of four parts: strateum corneum, epidermis, dermis, and
hypodermis. The relative thickness of each layer is shown. b) The thickness and refractive index of pork skin.[86] c) The thickness of the rabbit skin which
applied in previous works.[86] d) The thickness and refractive index of rat skin in previous works.[86] e) The thickness and refractive index of chicken
skin in previous works.[86] f) The skins in different locations of the human body which are applied in previous work.[91] g) The refractive indexes of the
different skin layers in the skin structure, which are based on a previous study.[119] h) The skin thickness according to panel (f).[91] i) The thickness of
fresh and fixed skins according to different locations of the human body.[91]
with different optical properties. The skin layers are the stratum
corneum, epidermis and dermis.[134]
Due to its similarity with human tissue, animal tissue is com-
monly used for in vivo testing of implantable PV cells. For exam-
ple, the thickness of porcine is between 2 mm to 4.5 mm, and its
refractive index is around 1.42, as shown in Figure 8a. Rabbit tis-
sue has also been used in the literature, and the PV implantation
depth was around 2 mm as in Figure 8b.[86] Since the application
is intraocular, the refractive index of the tissue was not consid-
ered. Other skin types that have been tested include rat skin. Its
thickness ranges from 0.7 to 1 mm,[119] and its refractive index is
between 1.40 and 1.42, as shown in Figure 8d.[119] Chicken mus-
cle also has similar properties to human muscle. The thickness
of chicken skin or muscles applied in the previous study is from 3
to 4 mm in Figure 8e.[119] Relatively, the hypodermis and muscle
refractive index are 1.45 and 1.399, respectively.
As previously mentioned, human skin is a complex heteroge-
neous medium. Therefore, greater light attenuation takes place
with depth due to the random spatial distribution of blood, chro-
mophores and pigments within skin tissue. Moreover, different
skin types will attenuate light differently due to age, ethnic group,
site of body, and gender.[56] Generally, skin is composed of four
main visible layers from the top surface: the blood-free epider-
mis (100–150 µm thick), vascularized dermis (1–4 mm thick),
and subcutaneous fat layer (hypodermis or adipose tissue) (1–6
mm thick various with different body parts).
The thicknesses and refractive indices of different skin types
are shown in Figure 8a,g. Furthermore, the epidermis can be di-
vided into two parts: the living part and the non-living part.[119]
The top layer is the strateum corneum, which is known as the
non-living epidermis (dead squamous cells only) and its thick-
ness varies from 10 to 20 µm. The strateum corneum is highly
keratinized with 20% lipid content, 60% protein content and
20% water content. The refractive index of strateum corneum
ranges between 1.47 and 1.51.[119] The living epidermis consists
of mostly pigments (most of them are melanin) compared with
the other tissues. The content of melanosome, a particle used to
produce melanin, varies from 1.3% (lightly pigmented) to 43%
(highly pigmented).[119] This pigment content is distinctive from
individual to individual, and higher pigment can result in higher
melanin absorptions as Figure 9a.
Dermis and epidermis are separated by a basal lamina, and
dermis is known as the main absorber of visible light accord-
ing to the blood haemoglobin, beta-carotene, and bilirubin in
the layer. The absorption of IR light is related to the water con-
tent in the dermis.[119] The absorption coefficients of different
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Figure 9. a) shows the absorption coefficient of human skin according to different wavelengths of the incident light. In the work of Bashkatov et al.
2011,[119] the skin properties in different locations from strateum to dermis are reported. b) The absorption coefficient according to the different light
spectra. The three ethnic groups including Caucasian, Asian, and African are analyzed in ref. [119]
skin layers are shown in Figure 9a, and the absorptions in the
visible spectral range are much higher than those in the IR re-
gion. For instance, the absorption coefficient of highly pigmented
epidermis is around 50 cm−1 at 650 nm while it is 10 cm−1 at
700 nm. The skin properties are also different from different eth-
nic groups, which is shown in Figure 9b. The absorption coeffi-
cients of the Caucasian (<1 cm−1) and the Asian skins (<1 cm−1)
are much smaller than that of African skins (>3.5 cm−1) when us-
ing 650 nm visible light. All the absorption coefficients of these
skins in three different ethnics saturates to 1 cm−1 when using
1000 nm NIR light. The optical absorptions in in vitro test is
smaller than those of in vivo test as well, and the water content
in the skins causes more absorptions as well. For example, when
using 650 nm visible light, the African skin has different absorp-
tion coefficient in vitro (2.2 cm−1) and in vivo (3.7 cm−1). Based on
the curves in Figure 7a,b, the NIR light shows the advantages:1.
Less attenuations compared with lower wavelength. 2. Majority
of types of skins including in vivo, in vitro, different ethnics and
different layers converge to 1 cm−1.
3.5. Biocompatibility
As most of the implantable PV cells are made from silicon, it
is quite necessary to investigate material degradation. The hy-
drolysis process of silicon materials can be simply interpreted as
the reaction between water vapor and silicon producing silicic
acid.[97] Plenty of factors affect the dissolution rates of c-Si, 𝜇c-Si
and a-Si, such as pH level and temperatures.[97] The silicon dis-
solution takes place when the silicon PV cell is implanted, which
ranges from 1 nm per day to 1 nm s−1 relying on the pH levels in
the ambient. The dissolution of different silicon structures at 37
Celsius in the butter solution is shown in Figure 10a–c.[97,135,136]
It is noticed that the polysilicon and a-Si have a slower dissolution
rate than that of the c-Si when comparing the slope in Figure 3a–
c. When the pH level is less than 7, the a-Si (>20 nm dissolution
in 15 days) will slightly dissolute faster than polysilicon (<20 nm
dissolution in 15 days). Moreover, silicon dissolution is also in-
fluenced by the doping profile in the layers.[97]
In vivo and in vitro testing is necessary to determine the bio-
compatibility and cytotoxicity of the implants. Due to the simi-
larity with human skin, testing is largely performed in chicken,
rats, pigs and rabbits.[80,86,89,95] There has also been testing of im-
plantable PV cells in different skin locations of the body.[91] More-
over, an ultrathin monocrystalline silicon solar cell array that in-
cludes the active layers, electrodes, interconnections and fully
biocompatible encapsulation layers was demonstrated in.[104] In
their study, the array was tested for seven days in vivo in a hair-
less rat. Cytotoxicity testing proved that between 89% to 91% of
cells were living after seven days, which means that there is min-
imal toxic effects, as shown in Figure 10e. Throughout the ex-
periment, the number of dead cells (9–18) is significantly lower
than the number of living cells (around 85–175), as shown in
Figure 10f, which indicates that there is good biocompatibility.
Further long-term testing in different skin locations is neces-
sary to determine the performance of these cells and to appre-
ciate the possible side effects of these implantable devices on the
wearer.[2]
In 2015, polysilicon thin-film PV cells were implanted in a
mouse.[97,136] The results show the fibroblast cell viability was
over 95% after seven days the similar results of a-Si, SiGe, Ge,
and mono-crystalline were also shown in Figure 10d.[136] In the
research of Song 2016, the survivability of the HDF cells extracted
from the IPV device is similar to that from the biocompatible ma-
terials, such as encapsulation-only or glass (Figure 10g). The sur-
vivability degraded massively when higher concentration from
toxic ZDEC-PU film (over 25%).[89]
Long-term in vivo or in vitro is a key factor to test the duration
of implantable devices under the skin. Only a few implantable
PV cells passed these tests, which are shown in Figure 10h. The
longest lifespan is achieved in a rabbit in 2004, and the cell sur-
vived over 7 months after implanted in retinal.[86] Despite the
previous retinal sample, the rest lifespans of PV cells are less
than 4 months according to the device failure or manually stop
the measuring process. This problem can be caused by the issue
mentioned in Section 3.4: no evidence has pointed out that the
polymer encapsulation can protect the integrated circuit in the
long term.
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Figure 10. a) The dissolution of crystalline silicon according to different pH levels at 37 °C, where lines are theoretical values and dots are experimental
values. b) The relative dissolution of poly silicon and c) a-Si. d) The viability of semiconductor materials which are normally used to fabricate implantable
photovoltaic cells. e) The viability of an implanted PV cells implemented.[92] f) The number of dead cells and living cells after PV cell was implanted.[92]
g) The survivability of the human dermal fibroblast cells after 24 h, extracted from implantable photovoltaic (IPV) device encapsulation layer only, glass,
and 0.1% zinc diethyldithiocarbamate (ZDEC) polyurethane (PU) film. h) The lifespan of the implantable device powered by photovoltaic cells in vivo
and in vitro. Reproduced with permission.[89] Copyright 2020, IEEE and Copyright Clearance Center.
4. Challenges and Future Development
PV energy harvesting is a mature technology that can be used for
implantable electronic devices.[94] However, there are a few chal-
lenges. First, semiconductor PV cells are rigid and expensive.
Organic PV cells can be an alternative to these semiconductor
technologies, provided that the efficiency and lifetime can be
improved. Typically, organic materials are much cheaper than
semiconductors and PV cell can be fabricated using solution-
based techniques in room temperature conditions. Second,
internal body heat reduces the efficiency of PV cells. Third, peo-
ple typically spend more time indoors, which means that these
devices will rely on indoor light for energy harvesting purposes.
Thus, the amount of harvestable energy is severely compromised.
In 2015, Haeberlin et al. tested the indoor performance (incident
power density of 4 W m−2 at a distance of 2 m from a closed
window without direct sunlight exposure) of the implantable PV
cell and reported a 4 µW cm−2 (1% of efficiency) output power
in in vivo test (female pork).[87,88] In 2018, Wu et al. used a 24 W
fluorescent lamp to test the PV cells (64×37 mm2) in indoor
conditions in vitro for pork skin. Only 120 µW of power was har-
vested, which was sufficient to supply the low-power consuming
biomedical sensors.[105] Consequently, implantable PV cells have
to be optimized for this type of lighting. Finally, even most of en-
capsulations for implantable PV cells are with high optical trans-
mittance, only polymer encapsulation can provide high flexibility
and comfortability, but more supportive evidence is required to
show their biocompatibility.
5. Conclusions and Recommendations
In summary, the factors which influence the performances of
different power harvesters. With the consideration in system
level, implantable PV cells are more promising in harvested
energy, smaller size, less complexity in power conversion, and
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flexible configurations. Considering the electrical performance,
the implantable PV cells are also advantageous for stable output
voltage and hundreds of mA current. With the development
of two decades, the great achievement has been made not only
in the off-chip instrument but on-chip measurement or even
in vitro and in vivo biocompatibility tests. The implantable PV
energy harvesting system is finalized with device fabrication,
on-chip power management circuitry and encapsulations. The
polymer encapsulation and hermetic package are applied to pro-
tect the PV cell from subcutaneous fluids. The mono-crystalline
silicon is mostly used in the implantable PV cell fabrication,
while the polysilicon and a-Si are advantageous for slower disso-
lution. Without encapsulation, the bio-performance of silicon is
much better than the other materials. The a-Si is promising with
the best performance in device viability, followed by mono-Si
and polysilicon. Nevertheless, the electrical output characteristic
of mono-silicon is much better than a-Si, and the polysilicon is
advantageous in material cost reduction. Turning the point to the
package and encapsulation, the cell viability of previous studies
shows that the implantable PV cell with encapsulation is highly
biocompatible. Two types of encapsulation structure can be used,
which are hermetic package and polymer encapsulation. The
hermetic structure is proposed with long-term stability in in vivo
test, while there is lack of evidence to show the stability of poly-
mer encapsulation in the implantable applications. It must be
emphasized that the comfortability and flexibility of the polymer
encapsulation is much better than the hermetic, while the her-
metic structure provide the better protection for the devices. The
other factors such as light source and optical skin loss can also
affect the performance of PV cell. The NIR light is confirmed as a
nice input power source of the implantable PV cells if the heating
problem can be solved. The human tissue various with different
ethnic group, different location, different age and even different
part of body in same person is summarized. The previous
research shows the African skin will cause more losses than that
of Caucasian and Asian. Moreover, it is also shown that the PV
cell in dermis can harvest move power than that in hypodermis,
while the cells in hypodermis can provide more stable energy.
The hand skin is one of the best parts to implant PV cells because
of the lower thickness. In popular believe, the in vivo test of
human implantation is far away from the PV cells now. The best
alternative subject is pork skin because of the similar thickness
and skin properties. In conclusion, the implantable PV cell is
advantageous in supplying the sufficient power within small
area compared with the other power harvesting techniques. The
circuitry of the PV cell is not as complex as the other AC source.
However, there are still some constrains of implantable PV cells:
Low feasibility and intensity of the light, rigid and expensive ma-
terials, penetration depth for PV cell to implant in surface area of
tissue and still need investigation on long term performance after
implantation.
Based on the literature review in this article, it is clear that
there has been plenty of interest in using PV cells for powering
implantable electronic devices. These cells have their limitations
and advantages. Their main advantage is the large power density
that can be generated. Their main limitation is the difficulty
in harnessing light due to tissue losses. However, since all
energy harvesters have their limitations, we believe that using a
hybrid harvester can help remedy this problem. Hybrid energy
harvesters are capable of scavenging energy from multiple
sources, thereby offsetting any limitations caused by the un-
availability of energy from one source. In this case, the system is
guaranteed to receive energy in case one or more energy sources
are unavailable.
Acknowledgements
This work was supported by grant EP/R511705/1 from EPSRC, UK, and the
European Union’s Horizon 2020 Hybrid Enhanced Regenerative Medicine
Systems (HERMES) project (GA n. 824164).
Conflict of Interest
The authors declare no conflict of interest.
Keywords
energy harvesting, implantable devices, photovoltaics
Received: May 8, 2020
Revised: July 9, 2020
Published online: July 29, 2020
[1] R. Das, F. Moradi, H. Heidari, IEEE Trans. Biomed. Circuits Syst. 2020,
14, 343.
[2] B. Shi, Z. Li, Y. Fan, Adv. Mater. 2018, 30, 1801511.
[3] X.-Y. Lang, H.-Y. Fu, C. Hou, G.-F. Han, P. Yang, Y.-B. Liu, Q. Jiang,
Nat. Commun. 2013, 4, 1.
[4] a) D. J. Ecker, R. Sampath, C. Massire, L. B. Blyn, T. A. Hall, M. W.
Eshoo, S. A. Hofstadler, Nat. Rev. Microbiol. 2008, 6, 553; b) J. Arlett,
E. Myers, M. Roukes, Nat. Nanotechnol. 2011, 6, 203.
[5] a) A.-H. Cavusoglu, X. Chen, P. Gentine, O. Sahin, Nat. Commun.
2017, 8, 617; b) M. Parvez Mahmud, N. Huda, S. H. Farjana, M.
Asadnia, C. Lang, Adv. Energy Mater. 2018, 8, 1701210; c) S. Gong,
W. Cheng, Adv. Energy Mater. 2017, 7, 1700648.
[6] Q. Zheng, B. Shi, F. Fan, X. Wang, L. Yan, W. Yuan, S. Wang, H. Liu,
Z. Li, Z. L. Wang, Adv. Mater. 2014, 26, 5851.
[7] Y. Jiang, M.-K. Law, P.-I. Mak, R. P. Martins, IEEE J. Solid-State Circuits
2018, 53, 3455.
[8] X. Liu, L. Huang, K. Ravichandran, E. Sánchez-Sinencio, IEEE J.
Solid-State Circuits 2016, 51, 1302.
[9] J. P. DiMarco, N. Engl. J. Med. 2003, 349, 1836.
[10] F. Rezai, Oral Surg., Oral Med., Oral Pathol. 1977, 44, 662.
[11] S. Park, X. Guan, Y. Kim, F. X. Creighton, E. Wei, I. Kymissis, H. H.
Nakajima, E. S. Olson, Trends Hear. 2018, 22, 2331216518774450.
[12] a) G. Clark, in Speech Processing in the Auditory System, Vol. 18,
Springer, New York 2004, p. 422; b) J. Žák, Z. Hadaš, D. Dušek, J.
Pekárek, V. Svatoš, L. Janák, J. Prášek, Mechatronics 2015, 31, 30.
[13] a) P. Song, S. Kuang, N. Panwar, G. Yang, D. J. H. Tng, S. C. Tjin, W. J.
Ng, M. B. A. Majid, G. Zhu, K. T. Yong, Adv. Mater. 2017, 29, 1605668;
b) R. Riahi, A. Tamayol, S. A. M. Shaegh, A. M. Ghaemmaghami, M.
R. Dokmeci, A. Khademhosseini, Curr. Opin. Chem. Eng. 2015, 7,
101.
[14] L. W. Kleiner, J. C. Wright, Y. Wang, J. Controlled Release 2014, 181,
1.
[15] a) T. Tokuda, T. Ishizu, W. Nattakarn, M. Haruta, T. Noda, K.
Sasagawa, M. Sawan, J. Ohta, AIP Adv. 2018, 8, 045018; b) K. Stingl,
K. U. Bartz-Schmidt, D. Besch, A. Braun, A. Bruckmann, F. Gekeler,
U. Greppmaier, S. Hipp, G. Hörtdörfer, C. Kernstock, A. Koitschev,
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (17 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
A. Kusnyerik, H. Sachs, A. Schatz, K. T. Stingl, T. Peters, B. Wilhelm,
E. Zrenner, Proc. Royal Soc. B: Biol. Sci. 2013, 280, 20130077.
[16] J. D. Weiland, W. Liu, M. S. Humayun, Annu. Rev. Biomed. Eng. 2005,
7, 361.
[17] G.-T. Hwang, M. Byun, C. K. Jeong, K. J. Lee, Adv. Healthcare Mater.
2015, 4, 646.
[18] K. Agarwal, R. Jegadeesan, Y.-X. Guo, N. V. Thakor, IEEE Rev. Biomed.
Eng. 2017, 10, 136.
[19] a) J. Zhao, R. Ghannam, M. K. Law, M. A. Imran, H. Heidari, IEEE
J. Elect. RF Microwaves Med. Biol. 2019, 4, 148; b) L. Bereuter, S.
Williner, F. Pianezzi, B. Bissig, S. Buecheler, J. Burger, R. Vogel, A.
Zurbuchen, A. Häberlin, Ann. Biomed. Eng. 2017, 45, 1172.
[20] S. Abdellatif, K. Kirah, R. Ghannam, A. Khalil, W. Anis, Appl. Opt.
2015, 54, 5534.
[21] a) S. O. Abdellatif, K. Kirah, R. Ghannam, A. Khalil, W. Anis, Int. J.
Recent Contrib. Eng. Sci. IT 2016, 4, 63; b) S. Abdellatif, R. Ghannam,
A. Khalil, Appl. Opt. 2014, 53, 3294.
[22] J. Li, J. Seo, I. Kymissis, M. Seok, IEEE J. Solid-State Circuits 2017, 52,
2550.
[23] K. Htet, R. Ghannam, Q. Abbasi, H. Heidari, IEEE Access 2018, 6,
42156.
[24] K. Oo Htet, R. Ghannam, Q. H. Abbasi, H. Heidari, IEEE Access 2018,
6, 42156
[25] M. Ashraf, N. Masoumi, IEEE Trans. Very Large Scale Integr. Syst.
2016, 24, 26.
[26] A. Cadei, A. Dionisi, E. Sardini, M. Serpelloni, Meas. Sci. Technol.
2013, 25, 012003.
[27] T. Tokuda, T. Ishizu, W. Nattakarn, M. Haruta, T. Noda, K. Sasagawa,
M. Sawan, J. Ohta, AIP Adv. 2018, 8, 045018.
[28] A. P. Chandrakasan, N. Verma, D. C. Daly, Annu. Rev. Biomed. Eng.
2008, 10, 247.
[29] V. Nabaei, R. Chandrawati, H. Heidari, Biosens. Bioelectron. 2018,
103, 69.
[30] X. Liang, R. Ghannam, H. Heidari, IEEE Sensors Journal 2019, 19,
1082.
[31] X. Wei, J. Liu, Front. Energy Power Eng. China 2008, 2, 1.
[32] H. Zhang, X.-S. Zhang, X. Cheng, Y. Liu, M. Han, X. Xue, S. Wang,
F. Yang, S. A. S, H. Zhang, Z. Xu, Nano Energy 2015, 12, 296.
[33] a) C. Fernandez, O. Garcia, J. Cobos, J. Uceda, presented at IEEE
34th Annual Power Electronics Specialist Conf., PESC’03, Acapulco,
Mexico, June 2003; b) I. Hochmair, P. Nopp, C. Jolly, M. Schmidt,
H. Schößer, C. Garnham, I. Anderson, Trends Amplif. 2006, 10, 201;
c) J. F. Patrick, P. A. Busby, P. J. Gibson, Trends Amplif. 2006, 10, 175.
[34] M. Gross, R. Buss, K. Kohler, J. Schaub, D. Jager, presented at the
First Joint BMES/EMBS Conf. 1999 IEEE Engineering in Medicine
and Biology 21st Annual Conf. and the 1999 Annual Fall Meet-
ing of the Biomedical Engineering Society, Atlanta, GA, October
1999.
[35] L. S. Wong, S. Hossain, A. Ta, J. Edvinsson, D. H. Rivas, H. Naas,
IEEE J. Solid-State Circuits 2004, 39, 2446.
[36] F. V. Y. Tjong, V. Y. Reddy, Circulation 2017, 135, 1458.
[37] R.-D. Battmer, G. M. O’donoghue, T. Lenarz, Ear Hear. 2007, 28,
95S.
[38] F.-G. Zeng, S. Rebscher, W. Harrison, X. Sun, H. Feng, IEEE Rev.
Biomed. Eng. 2008, 1, 115.
[39] A. Björklund, U. Stenevi, Annu. Rev. Neurosci. 1984, 7, 279.
[40] M. S. Humayun, L. C. O. de Koo, Retinal Prosthesis: A Clinical Guide
to Successful Implementation, Springer, New York 2018.
[41] P. J. Blackshear, F. Dorman, P. Blackshear, R. Varco, H. Buchwald,
Surg., Gynecol. Obstet. 1972, 134, 51.
[42] T. Hehn, Y. Manoli, in CMOS Circuits for Piezoelectric Energy Har-
vesters, Springer, Berlin 2015, pp. 21–40.
[43] W. Heimisch, S. Hagl, K. Gebhardt, N. Mendler, H. Meisner, in
Physics in Medicine and Biology, Vol. 25, No. 5, IOP Publishing Ltd,
Bristol, England 1980.
[44] A. Khaligh, P. Zeng, C. Zheng, IEEE Trans. Ind. Electron. 2009, 57,
850.
[45] A. Khan, Z. Abas, H. S. Kim, I.-K. Oh, Smart Mater. Struct. 2016, 25,
053002.
[46] Y. Yu, H. Sun, H. Orbay, F. Chen, C. G. England, W. Cai, X. Wang,
Nano Energy 2016, 27, 275.
[47] X. Cheng, X. Xue, Y. Ma, M. Han, W. Zhang, Z. Xu, H. Zhang, H.
Zhang, Nano Energy 2016, 22, 453.
[48] Q. Shi, T. Wang, C. Lee, Sci. Rep. 2016, 6, 24946.
[49] C. Dagdeviren, B. D. Yang, Y. Su, P. L. Tran, P. Joe, E. Anderson, J.
Xia, V. Doraiswamy, B. Dehdashti, X. Feng, Proc. Natl. Acad. Sci. USA
2014, 111, 1927.
[50] S. Ozeri, D. Shmilovitz, S. Singer, C.-C. Wang, Ultrasonics 2010, 50,
666.
[51] J. Rao, G. Richter, E. Weidlich, M. Wenzel, Biomed. Eng. 1974, 9, 98.
[52] A. A. Babadi, S. Bagheri, S. B. A. Hamid, Biosens. Bioelectron. 2016,
79, 850.
[53] M. Zhou, L. Deng, D. Wen, L. Shang, L. Jin, S. Dong, Biosens. Bio-
electron. 2009, 24, 2904.
[54] J. Y. Lee, H. Y. Shin, S. W. Kang, C. Park, S. W. Kim, Biosens. Bioelec-
tron. 2011, 26, 2685.
[55] J. Katic, S. Rodriguez, A. Rusu, IEEE Trans. Power Electron. 2017, 33,
4125.
[56] Y. Tan, W. Deng, B. Ge, Q. Xie, J. Huang, S. Yao, Biosens. Bioelectron.
2009, 24, 2225.
[57] A. Cuadras, M. Gasulla, V. Ferrari, Sens. Actuators, A 2010, 158, 132.
[58] M. Rudnicki, R. Chesworth, L. Harmison, Trans. Am. Nucl. Soc. 1970,
13, 503.
[59] S. Sedky, A. Kamal, M. Yomn, H. Bakr, R. Ghannam, V. Leonov,
P. Fiorini, presented at TRANSDUCERS 2009—Int. Solid-State Sen-
sors, Actuators and Microsystems Conf., Denver, CO, June 2009.
[60] E.-J. Yoon, J.-T. Park, C.-G. Yu, Front. Inf. Technol. Electron. Eng. 2018,
19, 285.
[61] G. Zhang, M. Li, H. Li, Q. Wang, S. Jiang, Energy Technol. 2018, 6,
791.
[62] W. Holcomb, W. Glenn, G. Sato, Med. Biol. Eng. 1969, 7, 493.
[63] L.-G. Tran, H.-K. Cha, W.-T. Park, Micro Nano Syst. Lett. 2017, 5, 14.
[64] S. Li, C. C. Mi, IEEE J. Emerging Sel. Topics Power Electron. 2015, 3, 4.
[65] D. A. Borton, M. Yin, J. Aceros, A. Nurmikko, J. Neural Eng. 2013,
10, 026010.
[66] T.-i. Kim, J. G. McCall, Y. H. Jung, X. Huang, E. R. Siuda, Y. Li, J. Song,
Y. M. Song, H. A. Pao, R.-H. Kim, Science 2013, 340, 211.
[67] C. T. Wentz, J. G. Bernstein, P. Monahan, A. Guerra, A. Rodriguez,
E. S. Boyden, J. Neural Eng. 2011, 8, 046021.
[68] S. Radiom, M. Baghaei-Nejad, K. Aghdam, G. A. Vandenbosch, L.-R.
Zheng, G. G. Gielen, IEEE J. Solid-State Circuits 2010, 45, 1746.
[69] Y. Shih, T. Shen, B. P. Otis, IEEE J. Solid-State Circuits 2011, 46, 2592.
[70] C. Liu, Y. Zhang, X. Liu, IEEE Antennas Wireless Propag. Lett. 2018,
17, 373.
[71] M. H. Ouda, M. Arsalan, L. Marnat, A. Shamim, K. N. Salama, IEEE
Trans. Microwave Theory Tech. 2013, 61, 2177.
[72] R. Ghannam, P. V. Klaine, M. Imran, in Solar Photovoltaic Power
Plants, Springer, New York 2019, p. 121.
[73] X. Li, N. P. Hylton, V. Giannini, K. H. Lee, N. J. Ekins-Daukes, S. A.
Maier, Prog. Photovoltaics 2013, 21, 109.
[74] S. Gong, W. Cheng, Adv. Energy Mater. 2017, 7, 1700648.
[75] J.-F. Chen, C.-L. Chun, Y. Hung, Jr., in 2015 Int. Symp. on Next-
Generation Electronics, IEEE, Piscataway, NJ 2015, p. 1.
[76] J. Charthad, M. J. Weber, T. C. Chang, A. Arbabian, IEEE J. Solid-State
Circuits 2015, 50, 1741.
[77] M. Schormans, V. Valente, A. Demosthenous, IEEE Trans. Biomed.
Circuits Syst. 2018, 12, 1112.
[78] Q. Zheng, H. Zhang, B. Shi, X. Xue, Z. Liu, Y. Jin, Y. Ma, Y. Zou, X.
Wang, Z. An, W. Tang, W. Zhang, F. Yang, Y. Liu, X. Lang, Z. Xu, Z.
Li, Z. L. Wang, ACS Nano 2016, 10, 6510.
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (18 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
[79] a) K. Shoji, Y. Akiyama, M. Suzuki, N. Nakamura, H. Ohno, K. Mor-
ishima, Biosens. Bioelectron. 2016, 78, 390; b) J. Schwefel, R. E. Ritz-
mann, I. N. Lee, A. Pollack, W. Weeman, S. Garverick, M. Willis, M.
Rasmussen, D. Scherson, J. Electrochem. Soc. 2015, 161, H3113;
c) K. MacVittie, J. Halámek, L. Halámková, M. Southcott, W. D.
Jemison, R. Lobel, E. Katz, Energy Environ. Sci. 2012, 6, 81; d) L.
Halámková, J. Halámek, V. Bocharova, A. Szczupak, L. Alfonta, E.
Katz, J. Am. Chem. Soc. 2012, 134, 5040.
[80] S. Ayazian, V. A. Akhavan, E. Soenen, A. Hassibi, IEEE Trans. Biomed.
Circuits Syst. 2012, 6, 336.
[81] Z. Chen, M.-K. Law, P.-I. Mak, R. P. Martins, IEEE Trans. Biomed.
Circuits Syst. 2017, 11, 44.
[82] a) M. A. Green, Y. Hishikawa, E. D. Dunlop, D. H. Levi, J. Hohl-
Ebinger, A. W. Y. Ho-Baillie, Prog. Photovoltaics 2018, 26, 3; b) M. A.
Green, Y. Hishikawa, W. Warta, E. D. Dunlop, D. H. Levi, J. Hohl-
Ebinger, A. W. Ho-Baillie, Prog. Photovoltaics 2017, 26, 3.
[83] M. K. Law, A. Bermak, IEEE Electron Device Lett. 2010, 31, 1425.
[84] G. Simone, D. Di Carlo Rasi, X. de Vries, G. H. Heintges, S.
C. Meskers, R. A. Janssen, G. H. Gelinck, Adv. Mater. 2018, 30,
1804678.
[85] A. V. Dan Tchin-Iou, B. G. Min, Int. J. Artif. Organs 1999, 22, 823.
[86] T. Laube, C. Brockmann, R. Buß, C. Lau, K. Höck, N. Stawski, T.
Stieglitz, H. A. Richter, H. Schilling, Graefe’s Arch. Clin. Exp. Oph-
thalmol. 2004, 242, 661.
[87] A. Haeberlin, A. Zurbuchen, J. Schaerer, J. Wagner, S. Walpen, C.
Huber, H. Haeberlin, J. Fuhrer, R. Vogel, EP Europace 2014, 16, 1534.
[88] A. Haeberlin, A. Zurbuchen, S. Walpen, J. Schaerer, T. Niederhauser,
C. Huber, H. Tanner, H. Servatius, J. Seiler, H. Haeberlin, J. Fuhrer,
R. Vogel, Heart Rhythm 2015, 12, 1317.
[89] K. Song, J. H. Han, T. Lim, N. Kim, S. Shin, J. Kim, H. Choo, S. Jeong,
Y.-C. Kim, Z. L. Wang, J. Lee, Adv. Healthcare Mater. 2016, 5, 1572.
[90] A. Ahnood, K. E. Fox, N. V. Apollo, A. Lohrmann, D. J. Garrett, D. A.
X. Nayagam, T. Karle, A. Stacey, K. M. Abberton, W. A. Morrison, A.
Blakers, S. Prawer, Biosens. Bioelectron. 2016, 77, 589.
[91] K. Song, J. H. Han, H. C. Yang, K. I. Nam, J. Lee, Biosens. Bioelectron.
2017, 92, 364.
[92] C. Yan, P. S. Lee, Small 2014, 10, 3443.
[93] E. Płaczek-Popko, Opto-Electron. Rev. 2017, 25, 55.
[94] M. A. Hannan, S. Mutashar, S. A. Samad, A. Hussain, Biomed. Eng.
Online 2014, 13, 79.
[95] E. Moon, D. Blaauw, J. D. Phillips, IEEE Trans. Electron. Devices 2017,
64, 2432.
[96] P. G. V. Sampaio, M. O. A. González, Renewable Sustainable Energy
Rev. 2017, 74, 590.
[97] X. Sheng, S. Wang, L. Yin, in Advances in Silicon Solar Cells, Springer,
New York 2018, p. 161.
[98] G. Bo, L. Ren, X. Xu, Y. Du, S. Dou, Adv. Phys.: X 2018, 3, 1446359.
[99] S. Sze, G. Gibbons, Appl. Phys. Lett. 1966, 8, 111.
[100] Y. Hung, Jr., M.-S. Cai, J.-F. Chen, H.-W. Su, P.-C. Jen, P. Chen, C.-C.
Shih, T.-C. Chang, IEEE J. Photovoltaics 2018, 8, 342.
[101] Y. Hung, Jr., T.-Y. Chuang, C.-L. Chun, M.-S. Cai, H.-W. Su, S.-L. Lee,
IEEE Trans. Electron. Devices 2014, 61, 4019.
[102] S. Il Park, G. Shin, A. Banks, J. G. McCall, E. R. Siuda, M. J. Schmidt,
H. U. Chung, K. N. Noh, J. G.-H. Mun, J. Rhodes, M. R. Bruchas, J.
A. Rogers, J. Neural Eng. 2015, 12, 056002.
[103] E. Moon, D. Blaauw, J. D. Phillips, IEEE Trans. Electron Devices 2017,
64, 15.
[104] L. Lu, Z. Yang, K. Meacham, C. Cvetkovic, E. A. Corbin, A. Vazquez-
Guardado, M. Xue, L. Yin, J. Boroumand, G. Pakeltis, T. Sang, K. J.
Yu, D. Chanda, R. Bashir, R. W. Gereau, X. Sheng, J. A. Rogers, Adv.
Energy Mater. 2018, 8, 1703035.
[105] T. Wu, J.-M. Redouté, M. R. Yuce, IEEE Access 2018, 6, 35801.
[106] Y. Arima, M. Ehara, IEICE Elect. Exp. 2006, 3, 287.
[107] K. Shen, M. M. Maharbiz, presented at the 9th Int. IEEE/EMBS Conf.
on Neural Engineering (NER), San Francisco, CA, March 2019.
[108] S.-H. Ahn, J. Jeong, S. J. Kim, Micromachines 2019, 10, 508.
[109] A. Vanhoestenberghe, N. Donaldson, J. Neural Eng. 2013, 10,
031002.
[110] M. R. Querry, Optical Constants, Missouri University, Kansas City,
MO 1985.
[111] D. L. Wood, K. Nassau, T. Kometani, D. Nash, Appl. Opt. 1990, 29,
604.
[112] T. T. S. Popova, V. Vorobev, Opt. Spectrosc. 1972, 33, 444.
[113] G. Ghosh, Opt. Commun. 1999, 163, 95.
[114] L. V. Rodríguez-de Marcos, J. I. Larruquert, J. A. Méndez, J. A.
Aznárez, Opt. Mater. Express 2016, 6, 3622.
[115] H. R. Philip, E. A. Taft, Phys. Rev. 1964, 136, A1445.
[116] M. R. Vogt, H. Holst, H. Schulte-Huxel, S. Blankemeyer, R. Witteck,
D. Hinken, M. Winter, B. Min, C. Schinke, I. Ahrens, Energy Procedia
2016, 92, 523.
[117] T. P. Otanicar, P. E. Phelan, J. S. Golden, Sol. Energy 2009, 83, 969.
[118] J. Li, C.-H. Wen, S. Gauza, R. Lu, S.-T. Wu, J. Disp. Technol. 2005, 1,
51.
[119] A. N. Bashkatov, E. A. Genina, V. V. Tuchin, J. Innovative Opt. Health
Sci. 2011, 4, 9.
[120] R. Caldwell, H. Mandal, R. Sharma, F. Solzbacher, P. Tathireddy, L.
Rieth, J. Neural Eng. 2017, 14, 046011.
[121] J. Jeong, F. Laiwalla, J. Lee, R. Ritasalo, M. Pudas, L. Larson, V. Leung,
A. Nurmikko, Adv. Funct. Mater. 2019, 29, 1806440.
[122] H. Fang, J. Zhao, K. J. Yu, E. Song, A. B. Farimani, C.-H. Chiang, X.
Jin, Y. Xue, D. Xu, W. Du, Proc. Natl. Acad. Sci. USA 2016, 113, 11682.
[123] a) V. Woods, M. Trumpis, B. Bent, K. Palopoli-Trojani, C.-H. Chiang,
C. Wang, C. Yu, M. N. Insanally, R. C. Froemke, J. Viventi, J. Neural
Eng. 2018, 15, 066024; b) K. Palopoli-Trojani, V. Woods, C.-H. Chi-
ang, M. Trumpis, J. Viventi, presented at the 38th Annual Int. Conf.
of the IEEE Engineering in Medicine and Biology Society (EMBC),
Orlando, FL, August 2016.
[124] S. W. Lee, K. S. Min, J. Jeong, J. Kim, S. J. Kim, IEEE Trans. Biomed.
Eng. 2011, 58, 2255.
[125] J. H.-C. Chang, Y. Liu, Y.-C. Tai, presented at the IEEE 27th Int. Conf.
on Micro Electro Mechanical Systems (MEMS), San Francisco, CA,
January 2014.
[126] H. Heidari, N. Wacker, R. Dahiya, Appl. Phys. Rev. 2017, 4, 031101.
[127] M. J. Weber, Handbook of Optical Materials, CRC Press, Boca Raton,
FL 2018.
[128] a) G. D. Wilk, R. M. Wallace, J. Anthony, J. Appl. Phys. 2001, 89, 5243;
b) J. Choi, Y. Mao, J. Chang, Mater. Sci. Eng., R 2011, 72, 97.
[129] D. Schaubroeck, R. Verplancke, M. Cauwe, D. Cuypers, K. Baumans,
M. Op de Beeck, presented at the XXXI Int. Conf. on Surface Modi-
fication Technologies (SMT31), Mons, Belgium, July 2017.
[130] S. Popova, T. Tolstykh, V. Vorobev, Opt. Spectrosc. 1972, 33, 444.
[131] I. Dion, C. Baquey, J. Monties, Int. J. Artif. Organs 1993, 16, 623.
[132] B. Ketola, K. R. McIntosh, A. Norris, M. K. Tomalia, presented at
the 23rd European Photovoltaic Solar Energy Conf., Valencia, Spain,
September 2008.
[133] S. L. Jacques, Phys. Med. Biol. 2013, 58, R37.
[134] a) P. A. Kolarsick, M. A. Kolarsick, C. Goodwin, J. Dermatol. Nurses’
Assoc. 2011, 3, 203; b) M. Geerligs, Ph.D. Thesis, Eindhoven Univer-
sity of Technology, 2010; c) R. R. Anderson, J. A. Parrish, J. Invest.
Dermatol. 1981, 77, 13.
[135] S. W. Hwang, G. Park, H. Cheng, J. K. Song, S. K. Kang, L. Yin, J.
H. Kim, F. G. Omenetto, Y. Huang, K. M. Lee, Adv. Mater. 2014, 26,
1992.
[136] S.-K. Kang, G. Park, K. Kim, S.-W. Hwang, H. Cheng, J. Shin, S.
Chung, M. Kim, L. Yin, J. C. Lee, ACS Appl. Mater. Interfaces 2015, 7,
9297.
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (19 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
Jinwei Zhao received a B.Eng. degree in electrical and electronics engineering, University of Edin-
burgh, 2016 and received an M.Sc. degree in electric power, Newcastle University, UK, 2017. He has
been a Ph.D. student at the University of Glasgow, since January 2018. The research interest is energy
harvesting, implantable systems and photovoltaic cells. He participated in the FDCT (The Science
and Technology Development Fund) funded project “High efficiency Energy Harvesting System for
Biomedical Devices” and exchanged to the State Key Laboratory of Analog and Mixed-signal VLSI
group (University of Macau) in 2019.
Rami Ghannam is a lecturer (assistant professor) in electronic and nanoscale engineering. Following
his Ph.D. from Cambridge University in 2007, he spent the past 10 years in the field of photovoltaics.
He has held previous appointments at Nortel Networks and IBM Research GmbH. He received his
B.Eng. degree from King’s College, as well as his DIC and M.Sc. degrees from Imperial College Lon-
don. He is currently investigating the use of energy harvesters for wearable and implantable electronic
devices. He is a member of the IET and a Senior Member of the IEEE.
Kaung Oo Htet was born in Yangon, Burma. He is currently doing his Ph.D. degree at the Microelec-
tronics Lab (meLAB) at the University of Glasgow. He received his M.Phil. degree in autonomous
power systems for bio devices from Newcastle University in 2016, M.Sc. (Merits) in automation and
control from Newcastle University in 2013 and B.Eng. (Hons) in electronic engineering from the Uni-
versity of Birmingham. He also achieved his BITE award (Distinctions) and HND foundation (Merits)
from Wigan and Leigh College in 2008–2009. His research interest is integrated power management
system for wearable and implantable devices.
Yuchi Liu received her B.Eng. degree in electronic information engineering, University of Electronic
Science and Technology of China in 2017 and received an M.Sc. degree in electrical and electronics
engineering, University of Glasgow, UK, 2018. She is currently a Ph.D. student at the University of
Glasgow, since February 2019. Her research interests mainly focus on wearable electronics, gesture
recognition, and piezoelectric sensors.
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (20 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
Man-Kay Law received his B.Sc. degree in computer engineering and the Ph.D. degree in electronic
and computer engineering from Hong Kong University of Science and Technology (HKUST), in 2006
and 2011, respectively. In February 2011, he joined HKUST as a visiting assistant professor. He is cur-
rently an assistant professor at the State Key Laboratory of Analog and Mixed-Signal VLSI, Faculty of
Science and Technology, University of Macau, Macau, China. His research interests are on the de-
velopment of ultra-low power CMOS sensing/readout circuits and energy harvesting techniques for
wireless and biomedical applications.
Roy Vellaisamy is a professor of intelligent systems at the James Watt School of Engineering, Univer-
sity of Glasgow. He works on multidisciplinary research blending device physics with materials chem-
istry and electronic engineering with particular focuses on intelligent devices and systems for sensing
application, wearable thermoelectrics, piezoresistive sensors, and neuromorphic devices.
Bruno Michel received a Ph.D. degree in biochemistry and computer engineering from the University
of Zurich and joined IBM Research to work on scanning probe microscopy and soft lithography. He im-
proved thermal interfaces and miniaturized convective cooling and demonstrated improved efficiency
and energy re-use in datacenters, and photovoltaic thermal solar concentrators. Recently he focusses
on integration of IoT and wearable devices with efforts spanning from sensing principles over efficient
miniaturized compute platforms to multi-sensor data fusion and cognitive computing. He is an IEEE
Fellow, a member of the US National Academy of Engineering and the IBM Academy of Technology.
Muhammad Ali Imran, Fellow IET, Senior Member IEEE, Senior Fellow HEA is a professor of wireless
communication systems with research interests in self-organized networks, wireless networked con-
trol systems and the wireless sensor systems. He heads the Communications, Sensing and Imaging
CSI research group at University of Glasgow. He is an affiliate professor at the University of Oklahoma,
USA, and a visiting professor at 5G Innovation Centre, University of Surrey, UK.
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (21 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
Hadi Heidari is a senior lecturer (associate professor) in the James Watt School of Engineering at the
University of Glasgow, UK. He is leading the Microelectronics Lab (meLAB) and his research includes
developing microelectronics for wearable and implantable devices. He is a member of the IEEE Cir-
cuits and Systems Society Board of Governors (2018–2020), IEEE Sensors Council Member-at-Large
(2020–2021), senior member of IEEE and Fellow of Higher Education Academy (FHEA). He is the
General Chair of the 27th IEEE ICECS 2020, and serves on the organizing committee of several confer-
ences.
Adv. Healthcare Mater. 2020, 9, 2000779 2000779 (22 of 22) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
